<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059748</url>
  </required_header>
  <id_info>
    <org_study_id>030173</org_study_id>
    <secondary_id>03-AR-0173</secondary_id>
    <nct_id>NCT00059748</nct_id>
  </id_info>
  <brief_title>Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis</brief_title>
  <official_title>Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Purpose:

      The purpose of this protocol is 1. To comprehensively evaluate patients with autoinflammatory
      diseases clinically, genetically and immunologically at the autoinflammatory disease clinic
      at the NIH. 2. To follow patients with autoinflammatory Diseases that are genetically defined
      including Neonatal-Onset Multisystem Inflammatory Disease (NOMID), the most severe clinical
      phenotype of Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency of IL-1 Receptor
      Antagonist (DIRA), Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated
      temperatures (CANDLE), and STING-Associated Vasculopathy with onset in Infancy (SAVI), and
      those with genetically undefined autoinflammatory disorders to determine long-term disease
      outcomes. 3. To develop biomarkers that help us assess disease activity and response to
      treatment. 4. To assess the eligibility of affected patients for inclusion in ongoing and
      planned treatment protocols.

      Goal: The goals of our studies are to understand the underlying immune dysregulation, to
      identify the genetic cause and to translate our findings into novel treatments that improve
      patients disease outcome.

      Eligibility:

        -  Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, and with
           other yet undifferentiated autoinflammatory diseases.

        -  Healthy adult and pediatric relatives.

        -  Volunteers

      Design:

      Participants will be evaluated at the NIH for 2-5 days. All participants will have a detailed
      medical history, physical exam, blood tests and other evaluations depending on the extend of
      their autoinflammatory disease.

      Participants may also expect the following assessments:

        1. Clinical test that help assess organ damage and functional impact such as hearing
           vision, memory and learning tests.

        2. Imaging studies to characterize the organ involvement of the inflammatory disease
           including: X-rays, CT scans, special MRIs, bone scans.

        3. Laboratory evaluations including clinical markers of disease activity, research samples
           for genetic studies, and blood samples for cytokine/biomarker assessment, and gene
           expression profiling.&lt;TAB&gt;

        4. Completion of questionnaires to assess disease activity and quality of life.

        5. If indicated, other procedures may be administered that include: a lumbar puncture if
           CNS inflammation is suspected and a skin biopsy if skin inflammation is present. other
           gastrointestinal procedures as they are clinically indicated.

        6. Patients my have a research skin biopsy taken.

      Participants may return for a single follow-up visits or for long term-follow up depending on
      their disease and willingness to be followed long-term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoinflammatory multisystem diseases are a group of diseases that are characterized by
      recurrent episodes of systemic inflammation as well as organ specific inflammation that can
      involve the skin, eyes, joints, bones, serosal surfaces, inner ear, and brain. The prominent
      role of IL-1 in the pathogenesis of these disorders has first become evident through the
      discovery of mutations in CIAS1 causing the cryopyrin-associated periodic syndromes (CAPS)
      including the most severe presentation Neonatal Onset Multisystem Inflammatory Disease
      (NOMID). Over the years we identified additional autoinflammatory diseases including DIRA
      (Deficiency of IL-1 Receptor Antagonist), a disease that is caused by mutations in IL1RN.
      Therapy with anakinra, the IL-1 receptor antagonist, can be life-saving. We also study
      additional rare diseases not IL-1 mediated including CANDLE (chronic atypical neutrophilic
      dermatosis with lipodystrophy and elevated temperatures) caused by mutations in proteasome
      components, and recently SAVI (STING associated vasculopathy with onset in infancy) caused by
      mutations in TMEM173, and juvenile dematomyositis (JDM) which shares some phenotypic features
      as well as an interferon (IFN) signature with SAVI and CANDLE. Many additional
      autoinflammatory phenotypes have no genetic causes, including autoinflammatory disorders that
      are not even clinically defined. Clinical conditions including the spectrum CRMO (Chronic
      Recurrent Multifocal Osteomyelitis), Still s disease, and Beh(SqrRoot)(Beta)et s disease (BD)
      with possible involvement of IL-1 dysregulation are also of interest.. In this research
      protocol we seek to comprehensively evaluate affected patients clinically, genetically,
      immunologically, and endocrinologically. In addition we intend to evaluate longterm outcomes
      and biomarkers over the time of observations. Eligibility for ongoing and planned treatment
      protocols will be determined by screening patients in this protocol. We plan to evaluate
      patients on a consultative basis for other autoinflammatory diseases for possible enrollment
      into this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2003</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of disease pathogenesis</measure>
    <time_frame>each visit</time_frame>
    <description>Clinical, immunological, genetic and endocrinological characteristics of the disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To develop long term clinical and laboratory outcome parameters of multiorgan involvement in patients and evaluation of blood, body fluid, and tissue biomarkers during disease flares and quiescence.</measure>
    <time_frame>each visit</time_frame>
    <description>Subject is determined to be eligible or not eligible for enrollment onto a treatment or intervention protocol.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Autoinflammatory Disease</condition>
  <condition>Juvenile Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>individuals affected by autoinflammatory multisystem diseases</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with auto inflammatory diseases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients with NOMID / CAPS or DIRA, CANDLE, SAVI, CRMO, Still's diseases, Behet's
             disease, JDM who are mutation positive for the disease or fulfill clinical criteria of
             the disease.

          -  Patients who have non-infectious osteolytic bone lesions

          -  Patients who fulfill criteria for definite or probable Still s disease

          -  Patients who fulfill criteria for definite or probable Behcet s disease

          -  Patients who fulfill criteria for definite or probable JDM

          -  Patients with other suspected autoinflammatory diseases

          -  There is:

               -  2 years old or older

               -  Patients or their legal guardians need to be able and willing to give informed
                  consent and a pediatric patient needs to be willing to assent to the protocol
                  whenever possible.

               -  No exclusion based on pregnancy status.

        Relatives of patients with autoinflammatory diseases or healthy volunteers may be included
        for genetic testing. The genetic evaluations will be conducted in collaboration with Dr.
        Fleisher s laboratory at the Clinical Center laboratory and other groups. See genetics
        consent form. We may also collect blood for serum and RNA analyses to establish a cohort of
        healthy controls that is matched in age, gender and ethnicity to the study patients. Skin
        biopsies for research may be requested from patients, patient relatives and healthy
        volunteers

        EXCLUSION CRITERIA:

          -  Active malignancy or any medical condition that in the opinion of the investigator
             would warrant exclusion

          -  Inability to return for follow up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Colbert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert A Colbert, M.D.</last_name>
    <phone>(301) 443-8935</phone>
    <email>colbertr@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2003-AR-0173.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Han S, Lin YC, Wu T, Salgado AD, Mexhitaj I, Wuest SC, Romm E, Ohayon J, Goldbach-Mansky R, Vanderver A, Marques A, Toro C, Williamson P, Cortese I, Bielekova B. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol. 2014 Mar 15;192(6):2551-63. doi: 10.4049/jimmunol.1302884. Epub 2014 Feb 7.</citation>
    <PMID>24510966</PMID>
  </reference>
  <reference>
    <citation>Sibley C, Yazici Y, Tascilar K, Khan N, Bata Y, Yazici H, Goldbach-Mansky R, Hatemi G. Beh√ßet syndrome manifestations and activity in the United States versus Turkey -- a cross-sectional cohort comparison. J Rheumatol. 2014 Jul;41(7):1379-84. doi: 10.3899/jrheum.131227. Epub 2014 Jun 15.</citation>
    <PMID>24931953</PMID>
  </reference>
  <verification_date>May 29, 2020</verification_date>
  <study_first_submitted>May 5, 2003</study_first_submitted>
  <study_first_submitted_qc>May 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2003</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myositis</keyword>
  <keyword>JDM</keyword>
  <keyword>Immune Dysregulation</keyword>
  <keyword>Skin Rash</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Neonatal Onset Multisystem Imflammatory</keyword>
  <keyword>Disease</keyword>
  <keyword>NOMID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

